Skip to main content
OSTEOPORE LIMITED logo

OSTEOPORE LIMITED — Investor Relations & Filings

Ticker · OSX ISIN · AU0000053324 ASX Manufacturing
Open in API
Filings indexed 488 across all filing types
Latest filing 2023-02-27 Annual Report
Country AU Australia
Listing ASX OSX

About OSTEOPORE LIMITED

https://osteopore.com

Osteopore Limited specializes in the design and manufacture of 3D-printed bioresorbable implants. The company utilizes a patented 3D printing process to create scaffolds from bioresorbable polymers, such as polycaprolactone, designed to mimic the natural microstructure of bone. These implants, including the Osteoplug, Osteomesh, and Osteostrip product lines, are applied in neurosurgical, craniofacial, and orthopedic procedures to facilitate bone healing and tissue regeneration. The scaffolds provide a temporary structural framework that supports the body's natural healing process before being gradually absorbed and replaced by the patient's own bone tissue. This technology aims to reduce long-term complications associated with permanent foreign implants by promoting natural tissue integration and restoration across various clinical applications.

Recent filings

Filing Released Lang Actions
Appendix 4E Preliminary Final Report 12 pages 215.5KB
Annual Report Classification · 95% confidence The document is titled 'Osteopore Limited and Its Controlled Entities Appendix 4E For the year ended 31 December 2022' and contains detailed financial statements including consolidated statements of profit or loss, financial position, changes in equity, and cash flows for the full year ended 31 December 2022. It includes notes to the preliminary financial statements, segment reporting, and accounting policies. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of comprehensive financial data and analysis for the full fiscal year aligns with the characteristics of an Annual Report (10-K equivalent). The document also states the financial statements are in the process of being audited, which is typical for annual reports. Therefore, this document is best classified as an Annual Report (10-K). FY 2022
2023-02-27 English
Osteopore Advisory Panel of Distinguished Industry Leaders 5 pages 327.3KB
Board/Management Information Classification · 95% confidence The document is an ASX release announcing the creation of an advisory panel with distinguished industry leaders joining Osteopore Limited. It contains no financial statements, no discussion of financial results, no regulatory certifications, no voting results, no capital changes, and no legal proceedings. It is a corporate announcement about management advisory appointments and strategic guidance. This fits best under Board/Management Information (MANG) as it relates to changes or additions in the company's advisory or management structure. The document length is over 10,000 characters and contains detailed information about the advisory panel members, supporting this classification with high confidence.
2023-02-26 English
Investor Presentation 28 pages 6.5MB
Investor Presentation Classification · 95% confidence The document is titled 'INVESTOR PRESENTATION' and contains detailed information about the company's technology, market opportunity, financial metrics, regulatory clearances, and recent achievements. It includes forward-looking statements, disclaimers, and detailed descriptions of products and market positioning. There is no indication that this is a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, audit report, or regulatory filing. The length (15,000 characters) and content are consistent with a presentation aimed at investors, focusing on strategy, technology, and market position rather than detailed financial statements. Therefore, the document fits the definition of an Investor Presentation (IP).
2023-02-19 English
OSX Enters Orthopaedic Market in Great Britain 3 pages 243.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX release announcing that Osteopore Limited's new product, aXOpore®, has been registered with the UK's Medicines & Healthcare products Regulatory Agency (MHRA), enabling its use in Great Britain. The content focuses on product registration, market entry, and future business plans. There are no financial statements, earnings data, management discussion of financial results, or regulatory filings related to financial performance. The document is a corporate announcement about product registration and market expansion, not a financial report or regulatory filing. Therefore, it fits best under the category of a general regulatory announcement or compliance update, which corresponds to Regulatory Filings (RNS). The document length is moderate and contains detailed information about the registration event, not just a brief notice of report publication or voting results. Hence, the classification is RNS with high confidence.
2023-02-13 English
Activities Update Qtr Ending December 2022 and Appendix 4C 10 pages 636.1KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX release from Osteopore Limited reporting record sales and financial performance for the full year 2022 and the quarter ended 31 December 2022. It includes detailed financial data such as revenue figures, cash balances, cash flow statements (Appendix 4C), and discusses operational highlights, acquisitions, and funding raised. The presence of the Appendix 4C quarterly cash flow report, which is a regulatory financial report required by the ASX, indicates this is a quarterly financial report. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly), not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q4 2022
2023-01-30 English
Appointment of Joint Company Secretary 1 page 165.2
Board/Management Information Classification · 100% confidence The document is an announcement from Osteopore Limited regarding the appointment of a new joint Company Secretary. It contains no financial data, no report or presentation, and no regulatory filings beyond the management change. The content focuses solely on a change in senior management personnel, specifically the appointment of Mrs Kellie Davis as joint Company Secretary. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and does not indicate any other report or filing type.
2023-01-24 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.